TMCnet

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% ...

Dual Imaging Identifies Cause of Heart Attack in Patients Without Blocked Arteries

When Ashley Perlow felt a sharp pain shoot across her chest and into both wrists, she didn't think it could be a heart attack ...

Managing Short-Term Expenses With Affordable Gold Loan Interest Rates

Managing short-term liquidity has become a strategic imperative for both families and small enterprises in this fast-paced financial environment. The gold market is still exhibiting incredible ...

MoonLake Immunotherapeutics AG: MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...

Planet TV Studios Announces New Frontiers Broadcast Featuring the Modular Building Institute, March 28th, 2026 on Bloomberg TV. The content in the episode is a Planet TV ...

The latest New Frontiers Series will air Saturday March 28th, 2026 on Bloomberg Television: Planet TV Studios proudly ...